INDEMNIFICATION AGREEMENTIndemnification Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
This INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into as of [—], 2014 between Vidara Therapeutics International Limited, a company formed under the laws of Ireland (the “Company”), and [—] (“Indemnitee”).
LEASE BY AND BETWEEN HUB PROPERTIES GA LLC, as Landlord and VIDARA THERAPEUTICS INC. (DE), as Tenant with respect to Holcomb Woods Business Park Roswell, GeorgiaLease • June 26th, 2014 • Vidara Therapeutics International LTD
THIS LEASE (this “Lease”) is made as of January 25, 2013, by and between Hub Properties GA LLC, a Maryland limited liability company (“Landlord”), and Vidara Therapeutics Inc. (DE), a Delaware corporation (“Tenant”).
LICENSE AGREEMENT FOR INTERFERON GAMMALicense Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • California
This Agreement is entered into effective as of May 5, 1998, (“Effective Date”) by and between Connetics Corporation, a Delaware corporation with its principal office at 3400 West Bayshore Road, Palo Alto, California 94303 (“Connetics”), and Genentech, Inc., a Delaware corporation with its principal office at 1 DNA Way, South San Francisco, California 94080 (“Genentech”).
CONSULTING AGREEMENTConsulting Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • Illinois
This Consulting Agreement (the “Agreement”) is entered into as of March 18, 2014 and shall become effective as of the Effective Date (as defined below), by and among Horizon Pharma USA, Inc., with its principal place of business at 520 Lake Cook Road, #520, Deerfield, IL 60015 (“Company”), and Virinder Nohria, M.D., Ph.D., an individual residing at 111 Skyline View Road, Franklin, NC 28734 (“Consultant”), for the purpose of setting forth the exclusive terms and conditions by which Company will acquire Consultant’s services on a temporary basis. Company and Consultant may be referred to herein individually as a “Party,” or collectively as the “Parties.”
ASSET PURCHASE AGREEMENT by and among Vidara Therapeutics International Limited (as Purchaser), Vidara Therapeutics Holdings LLC (as Parent), Vidara Therapeutics Research Limited (as Opco) and InterMune, Inc. (as Seller) May 17, 2012Asset Purchase Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • Delaware
This ASSET PURCHASE AGREEMENT (as amended from time to time, the “Agreement”), dated as of May 17, 2012 (the “Agreement Date”), is made and entered into by and among Vidara Therapeutics International Limited, an Irish company (“Purchaser”), Vidara Therapeutics Holdings LLC, a Delaware limited liability company (“Parent”), Vidara Therapeutics Research Limited, an Irish company (“Opco”) and InterMune, Inc., a Delaware corporation (“Seller”). Purchaser, Parent, Opco and Seller are sometimes collectively referred to herein as the “Parties” and separately as a “Party.”
AMENDMENT NO. TWO TO LICENSE AGREEMENTLicense Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
THIS AMENDMENT NUMBER TWO TO LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective January 15, 1999, by and between Genentech, Inc. (“Genentech”) and Connetics Corporation (“Connetics”).
Dated the 16th day of April 2012 BENTON PROPERTY HOLDING LIMITED (IN RECEIVERSHIP) (1) and JIM HAMILTON (2) and VIDARA THERAPEUTICS (3) LICENCE AGREEMENT Re: Unit Nos. 202 and 203 Second Floor Adelaide Chambers Peter Street Dublin 8 Eversheds...Licence Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
ASSIGNMENT AND OPTION AGREEMENT BY AND BETWEEN INTERMUNE PHARMACEUTICALS, INC. AND CONNETICS CORPORATION JUNE 23, 2000 (SUPERSEDING AND REPLACING THE AMENDED AND RESTATED EXCLUSIVE SUBLICENSE AGREEMENT OF APRIL 27, 1999)Assignment and Option Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • California
THIS ASSIGNMENT AND OPTION AGREEMENT (the “Agreement”) is made effective and entered into as of June 23, 2000 (the “Effective Date”) by and between CONNETICS CORPORATION, a Delaware corporation, with a principal place of business at 3400 West Bayshore Road, Palo Alto, CA 94303 (“Connetics”), and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010 (“InterMune”). Connetics and InterMune may be referred to herein as a “Party” or collectively as the “Parties.”
CONSOLIDATED SUPPLY AGREEMENTConsolidated Supply Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • New York
THIS CONSOLIDATED SUPPLY AGREEMENT (this “AGREEMENT”), is made effective as of the 31 day of July 2013 (the “EFFECTIVE DATE”) by and between Vidara Therapeutics Research, Ltd. (“VIDARA”), an Irish corporation, having an address at Adelaide Chambers, Peter Street, Dublin 8, Ireland and Boehringer Ingelheim RCV GmbH & Co KG (“BI RCV”), an Austrian limited liability partnership, having its registered office at Dr. Boehringer-Gasse 5 – 11, A-1121 Vienna, Republic of Austria (and successor-in-interest of Boehringer Ingelheim Austria GmbH). VIDARA and BI RCV may be referred to herein each individually as a “Party” and jointly as the “Parties.”
REVENUE ADJUSTMENT AGREEMENT BY AND BETWEEN INTERMUNE PHARMACEUTICALS, INC. AND CONNETICS CORPORATION JUNE 27, 2000Revenue Adjustment Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • California
THIS REVENUE ADJUSTMENT AGREEMENT (the “Agreement”) is made effective and entered into as of June 27, 2000 (the “Effective Date”) by and between CONNETICS CORPORATION, a Delaware corporation, with its principal place of business at 3400 West Bayshore Road, Palo Alto, CA 94303 (“Connetics”), and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with its principal place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010 (“InterMune”). Connetics and InterMune may be referred to herein as a “Party” or collectively as the “Parties.”
AMENDMENT NO. ONE TO LICENSE AGREEMENTLicense Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
THIS AMENDMENT NUMBER ONE TO LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective December 28, 1998, between Genentech, Inc. (“Genentech”) and Connetics Corporation (“Connetics”). Terms not otherwise defined in this Amendment shall have the meanings as defined in the License Agreement.
AMENDMENT TO ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
This AMENDMENT TO ASSET PURCHASE AGREEMENT (the “Amendment”), dated as of June 18, 2012, is made and entered into by and among Vidara Therapeutics International Limited, an Irish company (“Purchaser”), Vidara Therapeutics Holdings LLC, a Delaware limited liability company (“Parent”), Vidara Therapeutics Research Limited, an Irish company (“Opco”) and InterMune, Inc., a Delaware corporation (“Seller”). Capitalized terms used herein and not otherwise defined herein shall have the meaning given such terms in the Agreement (as defined below).
AMENDMENT NO. THREE TO LICENSE AGREEMENTLicense Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
THIS AMENDMENT NUMBER THREE TO LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective April __, 1999 (the “Amendment Effective Date”), by and between Genentech, Inc. (“Genentech”) and Connetics Corporation (“Connetics”). Genentech and Connetics may each be referred to herein as a “Party” and jointly as the “Parties.”
January 25, 2001 Ms. Anna Hall Director of Business Development Genentech, Inc.License Agreement • June 26th, 2014 • Vidara Therapeutics International LTD
AMENDMENT No. 6 to the License Agreement for Interferon GammaLicense Agreement for Interferon Gamma • June 26th, 2014 • Vidara Therapeutics International LTD
THIS AMENDMENT NUMBER SIX TO THE LICENSE AGREEMENT FOR INTERFERON GAMMA (“Amendment”) is entered into effective February, 2006 (the “Amendment Effective Date”), by and between Genentech, Inc. (“Genentech”) and InterMune, Inc. (“InterMune”). Genentech and InterMune may each be referred to herein as a “Party” and jointly as the “Parties.”
CONSENT TO ASSIGNMENT AGREEMENT BETWEEN CONNETICS AND INTERMUNE PHARMACEUTICALS, INC. JUNE 23, 2000Consent to Assignment Agreement • June 26th, 2014 • Vidara Therapeutics International LTD • California
THIS CONSENT TO ASSIGNMENT AGREEMENT (this “Agreement”) is made effective and entered into as of June 23, 2000 (the “Effective Date”) by and between GENENTECH, INC., a Delaware corporation, with a principal place of business at 1 DNA Way, South San Francisco, California 94080 (“Genentech”), CONNETICS CORPORATION, a Delaware corporation, with a principal place of business at 3400 Bayshore Road, Palo Alto, California 94303 (“Connetics”) and INTERMUNE PHARMACEUTICALS, INC., a Delaware corporation, with a principal place of business at 1710 Gilbreth Road, Suite 301, Burlingame, CA 94010 (“InterMune”). Genentech, Connetics and InterMune may be referred to herein as a “Party” or collectively as the “Parties.”
SEVENTH AMENDMENT TO LICENSE AGREEMENT FOR INTERFERON GAMMALicense Agreement for Interferon Gamma • June 26th, 2014 • Vidara Therapeutics International LTD
This Seventh Amendment To License Agreement for Interferon Gamma (hereinafter “Seventh Amendment”) is entered into effective December 17, 2013 (the “Seventh Amendment Effective Date”) by and between Genentech, Inc, (“Genentech”) and Vidara Therapeutics International Limited, (“Vidara”), who are now Parties to the License Agreement for Interferon Gamma dated May 5, 1998, as amended. Genentech and Vidara may each be referred to herein as a “Party” and jointly as the “Parties.”
